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Abstract
Humoral hypercalcemia of malignancy (HHM) is most commonly encountered in squamous cell
carcinoma (SCC) of different organs, and It is characterized by elevated parathyroid hormonerelated peptide (PTHrP) levels. It may be seen as a manifestation of cholangiocarcinoma (CCC)
at presentation and later in the course of the disease. However, HHM due to intrahepatic
cholangiocarcinoma is a rare association and is associated with a poor prognosis.
We herein report a case of hypercalcemia presenting as the first manifestation of an
underlying rare variant of intrahepatic cholangiocarcinoma. Our patient is a 57-year-old male
who presented to the emergency room with severe symptoms of constipation and polyuria and
was admitted to the hospital for symptomatic hypercalcemia. He was found to have a
hypermetabolic 15 cm liver mass, abdominal lymph nodes on imaging, which was subsequently
diagnosed as adenosquamous cholangiocarcinoma by liver biopsy. This necessitated an urgent
inpatient treatment with gemcitabine/cisplatin combination chemotherapy to control the
aggressive nature of the malignancy. However, he deteriorated and expired after three months
of his diagnosis.
Adenosquamous cholangiocarcinoma is a very rare variant of a liver tumor. It develops due to
squamous metaplasia of an underlying cholangiocarcinoma and usually has aggressive
clinicopathological features. HMM is a life-threatening, yet unrecognized, phenomenon of
cholangiocarcinoma, which represents a poor prognostic marker. Prompt recognition of this
complication is important for preventing serious complications associated with hypercalcemia
and to improve the quality of life of these patients.
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Introduction
Hypercalcemia of malignancy is seen in up to 30% of all cancers via four different mechanisms:
humoral hypercalcemia of malignancy (HHM), local osteolytic hypercalcemia, excess
1,25(OH)2D secretion, and ectopic parathyroid hormone secretion [1]. Parathyroid hormonerelated peptide (PTHrP) secretion is the most common mechanism (80%) causing hypercalcemia
of malignancy [1-2]. Even though HHM theoretically can be seen in any type of cancer, it is very
rarely seen with cholangiocarcinoma, as in our case [3].
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Case Presentation
A 67-year-old Hispanic male presented to the emergency department with gradually worsening
complaints of generalized body weakness, difficulty sleeping, abdominal pain, increased
thirst with urinary frequency, and constipation for the last two months. He had a past medical
history of a fatty liver secondary to alcohol use and a four-pack per year smoking history. The
initial physical examination was unremarkable with normal vital signs except for
hepatomegaly. The laboratory data on admission are summarized in Table 1.

Normal Range

Result

White Blood Cell Count

4.10 - 10.10 10x9/L

17.60 (H)

Hemoglobin

12.9 - 16.7 g/dL

12.7 (L)

Mean Corpuscular Volume

80.8 - 94.1 fL

86.5

Platelet Count

153 - 328 10x9/L

422 (H)

Absolute Neutrophil Count

1.40 - 6.80 10x9/L

12.80 (H)

Absolute Lymphocyte Count

1.10 - 2.90 10x9/L

2.60

Absolute Monocyte Count

0.20 - 1.00 10x9/L

1.20 (H)

Absolute Eosinophil Count

0.00 - 0.40 10x9/L

0.80 (H)

Absolute Basophil Count

0.00 - 0.10 10x9/L

0.20 (H)

International Normalized Ratio

0.70 - 1.20

1.08

Blood Urea Nitrogen

9.0 - 20.0 mg/dL

18.0

Creatinine

0.66 - 1.25 mg/dL

0.94

Sodium

133 - 145 mEq/L

134

Potassium

3.5 - 5.1 mEq/L

4.1

Chloride

98 - 107 mEq/L

96 (L)

CO2

22 - 30 mEq/L

31 (H)

Calcium

8.4 - 10.5 mg/dL

15.2 (H)

Phosphorus

2.5 - 4.5 mg/dL

2.9

Total Protein

6.3 - 8.2 g/dL

6.4

Albumin

3.5 - 5.0 g/dL

3.4 (L)

Total Bilirubin

0.2 - 1.3 mg/dL

0.5

Alanine Aminotransferase

21 - 72 U/L

29

Aspartate Aminotransferase

17 - 59 U/L

20
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Alkaline Phosphatase

38.0 - 126.0 U/L

141.0 (H)

Gamma-Glutamyl Transferase

15 - 73 U/L

276

Magnesium

1.6 - 2.3 mg/dL

1.4 (L)

Parathyroid Hormone0Related Protein

14-27 pg/ml

82(H)

Alfa Fetoprotein

<6.1 ng/mL

2.2

Cancer Antigen 19-9

<34 U/mL

140 (H)

Carcinoembryonic Antigen

0.0 - 2.4 ng/mL

1.5

Intact Parathyroid Hormone

14 - 64 pg/mL

2 (L)

Vitamin D,1,25-(OH)2

18 - 72 pg/mL

31

TABLE 1: Initial laboratory investigations

The initial laboratory evaluation showed leukocytosis (white blood cell count of 16.60 10x9/L),
normal kidney function, elevated corrected calcium level of 15.5 mg/dL, elevated alkaline
phosphatase level of 141 U/L (normal range 38.0-126.0 U/L), and normal phosphorus level of
2.9 mg/dl (normal range 2.5 - 4.5 mg/dl). Intact parathyroid level was found to be low at 2 pg/ml
(normal range 14-64 pg/ml). However, parathyroid hormone-related peptide level (PTHrP) was
high at 82 pg/ml (normal range 14-27 pg/ml). His other laboratory values included low vitamin
D,25-Hydroxy level of 13.4 ng/ml (normal range 30-100 ng/ml), carcinoembryonic antigen
(CEA) level of 1.5 ng/mL (normal range: <5.0 ng/mL), carbohydrate antigen (CA) 19-9 level of
140 U/mL (normal range: <34 U/mL), α-fetoprotein (AFP) level of 1.6 ng/mL (normal range: <
6.1 ng/mL), and serum protein electrophoresis was within normal limits. He had negative viral
serology for hepatitis B, hepatitis C, Epstein Barr Virus, cytomegalovirus, and human
immunodeficiency virus. A computerized tomography (CT) scan of the abdomen and pelvis
with intravenous contrast was performed to evaluate the etiology of abdominal pain, which
revealed a large complex appearing mass within the liver appearing as multifocal lesions with a
large central hypodense lesion and numerous peripheral satellite lesions; the largest
component of the mass measured 19.1 x 14.7 cm (Figure 1). There was also mild intrahepatic
bile duct dilatation, most likely due to mass-effect on the porta hepatis, and haziness within the
fat inferior to the liver, which was concerning for peritoneal carcinomatosis.

FIGURE 1: Computerized tomography of the abdomen with
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intravenous contrast showing a large, complex-appearing
mass within the liver appearing as multifocal lesions with a
large central hypodense lesion (red arrow) and numerous
peripheral satellite lesions (blue arrows); the largest
component of the mass measured 19.1 x 14.7 cm

The patient was admitted to the hospital and received treatment with intravenous fluid
resuscitation, calcitonin, and zoledronic acid for hypercalcemia of malignancy. Further
evaluation with positron emission tomography-computed tomography (PET-CT) reported
extensive hyper-metabolic activity in the liver, which corresponded to a large, complex cystic
mass and multiple satellite lesions on CT images, consistent with malignancy. In addition, It
revealed hypermetabolic, small, and mildly enlarged upper abdominal lymph nodes, mildly
hypermetabolic activity in the omentum/peritoneum, and ascites; all these findings were
suspicious for metastatic disease. Lastly, there were small scattered pulmonary nodules, which
were below the size resolution of PET imaging. CT-guided biopsy of the liver was performed,
and pathology showed poorly differentiated adenocarcinoma with squamous features
supportive of pancreaticobiliary as primary (Figure 2). Tumor cells were positive for CEA, CK19,
P63, CK5/6, focally positive for CK7, and negative for CK20 and hepatocyte stains (Figure 3).

FIGURE 2: Liver core biopsy, H & E stain, poorly differentiated
adenocarcinoma with squamous features (10X on the left and
50X on the right)
H & E: hematoxylin and eosin

FIGURE 3: Liver core biopsy, 10X. Immunohistochemical stain
CK19 positive, favor pancreatic-biliary primary (left). Liver core
biopsy, 10X. Immunohistochemical stain CK5/6 positive, favor
2019 Erdinc et al. Cureus 11(12): e6481. DOI 10.7759/cureus.6481
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squamous features (right)

Chemotherapy with cisplatin and gemcitabine was started after the diagnosis was confirmed.
However, the patient had recurrent admissions with worsening symptoms and uncontrolled
hypercalcemia. His course was also complicated further with acute kidney injury, cholestatic
hyperbilirubinemia, and pancreatitis and required placement of percutaneous transhepatic
cholecystostomy (PTC). The patient’s condition further deteriorated, and he expired within
three months of his diagnosis.

Discussion
Cholangiocarcinoma is a very aggressive tumor and comprises about 3% of all gastrointestinal
malignancies [4]. Studies on this rare type of tumor are only limited to case reports or small
case series [2,5-6]. Primary sclerosing cholangitis (PSC), fibropolycystic liver disease,
hepatolithiasis, chronic viral hepatitis, and a few genetic conditions, such as Lynch syndrome,
BRCA-associated protein-1 (BAP1) tumor predisposition syndrome, cystic fibrosis, and biliary
papillomatosis are among the common risk factors for cholangiocarcinoma [7]. Toxic exposure
to thorotrast (previously used radiocontrast agent) [8], parasitic infections with Clonorchis and
Opisthorchis [9], and human immunodeficiency virus (HIV) infection [10] have also proved to
have a relationship with cholangiocarcinoma.
Adenosquamous cholangiocarcinoma (ASC) is a rare variant of cholangiocarcinoma, which was
first described by Barr and Hancock in 1975 [11] and consists of malignant glandular and
squamous components. Tumor cells have both mucin-producing glandular structures as in
adenocarcinoma and irregularly shaped solid nests of polygonal cells with distinct
cellular borders, eosinophilic cytoplasm, varying degrees of keratinization, and intercellular
bridges as in squamous cell cancer [12-13]. Cholangiocarcinoma with squamous features have
been previously described as ASC but also as mucoepidermoid carcinoma (mucus-producing
cells and squamoid cells without keratin formation) and adenoacanthoma (squamous
metaplasia) [6,14]. The prognosis of ASC is extremely poor even with surgery and most patients
are not candidates for surgery and chemotherapy at presentation [2,6,12]. Nakajima and Kondo
[2] evaluated 11 patients with ASC and compared their prognosis with 82
cholangiocarcinoma patients with adenocarcinoma features and found that the mean overall
survival was four months in ASC patients versus 6.9 months in the latter.
HHM is caused by PTH-related peptide (PTHrP) by malignant tumors, such as squamous cell
carcinoma, renal cell carcinoma, ovarian cancer, endometrial cancer, lymphoma, and breast
cancer [1]. PTHrP has different identified functions, such as proliferation and differentiation in
chondrocytes [15], regulation of calcium level in the placenta [16], calcium reabsorption in renal
cells, resorption of calcium from osteocytes [17], and browning of adipose cells and cachexia
[18-19]. PTHrP secreting cancer cells can be detected, for diagnostic and research purposes,
with immunohistochemical stains (PTHrP antibody stain). Even though HMM has been
previously described in different types of cancers, it is an unrecognized phenomenon of
cholangiocarcinoma and associated with a very poor prognosis [20]. For this reason, the early
detection and treatment of HHM is essential. The treatment of HHM should include immediate
treatment with intravenous hydration and calcitonin and long-term treatment with
bisphosphonates and denosumab. Hemodialysis is usually reserved for patients with severe
hypercalcemia.

Conclusions
Our case is an example of metastatic adenosquamous cholangiocarcinoma without bony
metastasis, presenting as hypercalcemia, secondary to PTHrP levels confirming the diagnosis of
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HHM. Adenosquamous cholangiocarcinoma, being a very rare variant of cholangiocarcinoma
presents with HHM, which is also a very rare presentation, as it is usually associated with other
types of cancers. Physicians should be aware of this rare presentation of cholangiocarcinoma, as
prompt recognition of this atypical presentation can prevent the serious complications
associated with hypercalcemia and improves the quality of life of these patients.
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